Premium
Early prediction of anthracycline induced cardiotoxicity
Author(s) -
Erkus Bedirhan,
Demirtas Selda,
Yarpuzlu Aysegul Akbay,
Can Murat,
Genc Yasemin,
Karaca Levent
Publication year - 2007
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.2006.00174.x
Subject(s) - medicine , cardiotoxicity , anthracycline , cardiology , chemotherapy , cancer , breast cancer
Aim: The purpose of this study is to evaluate echocardiographically determined cardiac functions with serum levels of brain natriuretic peptide (BNP), cardiac troponin I (cTnI) and total antioxidant status (TAOS) in childhood leukemia treated with chemotherapeutics containing anthracyclines. Methods: A study group of 29 patients who have been followed for acute lymphoblastic leukemia (ALL) and administered a treatment protocol containing chemotherapy of anthracyclines were included in the analysis. Levels of BNP, cTnI and TAOS were studied in serum samples of the patients. Results: We demonstrated that as the drug dosage increased, systolic ejection fraction (EF) and shortening fraction (FS) values decreased (EF r 2 = 0.2327, FS r 2 = 0.251). On the other hand, increased dosage of anthracycline therapy was associated with significant raise in plasma BNP levels (r 2 = 0.246) and significant decrease in serum TAOS levels (r 2 = 0.317) without any change in serum cTnI levels. Conclusion: Our study suggest that serum TAOS and BNP levels may be useful as an early and sensitive indicator of anthracycline induced cardiotoxicity.